FrancophonIA/ELRC3.0 huggingface dataset:
English: Summary of Stead-State Plasma Lamivudine AUC (0-24) (µg•h/mL) and Statistical Comparisons for Once and Twice-Daily Oral Administration Across Studies
Maltese: Sommarju tal-AUC ta' Lamivudine fil-Plażma fi Stat Fiss (0-24) (µg•h/mL) u Paraguni Statistiċi għal Għoti Orali ta' Darba Kuljum u Darbtejn Kuljum fl-Istudji Kollha
English: PENTA 13
Maltese: Pallagi út 13
English: Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
Maltese: Lamivudine huwa analogu nuklejosida li għandu attività kontra l-virus ta' immunodefiċjenza fil-bniedem (HIV) u l-epatite B (HBV).
English: The 150 mg tablet is bioequivalent and dose proportional to the 300 mg tablet with respect to AUC∞, Cmax, and tmax.
Maltese: Il-pillola ta' 150 mg hi bijoekwivalenti u proporzjonali fid-doża għall-pillola ta' 300 mg fir-rigward tal-AUC∞, Cmax, and tmax.
English: Rare: Hepatitis.
Maltese: infjammazzjoni (epatite).
English: • cladribine (used to treat hairy cell leukaemia).
Maltese: • cladribine (użat għall-kura ta' lewkimja ta' ċelloli sufin).
English: An interaction with trimethoprim, a constituent of co-trimoxazole, causes a 40% increase in lamivudine exposure at therapeutic doses.
Maltese: L-effetti fuq trimethoprim, kostitwent ta' co-trimoxazole, jikkawżaw żieda ta' 40% fl-espożizzjoni ta' lamivudine f'dożi terapewtiċi.
English: The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Maltese: PSURs għal dan il-prodott mediċinali huma mniżżla fil-lista taddati ta' referenza tal-Unjoni (lista EURD) prevista skont l-Artikolu 107c(7) tadDirettiva 2001/83/KE u kwalunkwe aġġornament sussegwenti ppubblikat fuq il-portal elettroniku Ewropew tal-mediċini.
English: Nervous system disorders Common: Headache, insomnia.
Maltese: Disturbi fis-sistema nervuża Komuni: Uġigħ ta' ras, insomnija.
English: Children weighing 14 kg to <20 kg: The recommended dose is 150 mg daily.
Maltese: Tfal li jiżnu minn 14 kg sa <20 kg: Id-doża rakkomandata hija 150 mg kuljum.
English: Administration of trimethoprim/sulfamethoxazole 160 mg/800 mg results in a 40% increase in lamivudine exposure, because of the trimethoprim component; the sulfamethoxazole component did not interact.
Maltese: L-għoti ta' 160 mg/800 mg trimethoprim/sulfamethoxazole jirriżulta f'żieda ta' 40% fl-esponiment ta' lamivudine, minħabba li fih trimethoprim;
English: Coadministration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC∞) and 28%, 52%, and 55% in the Cmax of lamivudine in adults.
Maltese: soluzzjoni orali ta' lamivudine rriżulta fi tnaqqis dipendenti fuq id-doża ta' 14%, 32%, u 36% flesponiment għal lamivudine (AUC∞) u 28%, 52%, u 55% fis-Cmax ta' lamivudine fl-adulti.
English: 1206 HIV-infected paediatric patients aged 3 months to 17 years were enrolled in the ARROW Trial (COL105677), 669 of whom received abacavir and lamivudine either once or twice daily (see section 5.1).
Maltese: 1,206 pazjenti pedjatriċi infettati bl-HIV li kellhom bejn 3 xhur u 17-il sena ġew irreġistrati fil-Prova ARROW (COL105677), 669 minnhom ingħataw abacavir u lamivudine darba jew darbtejn kuljum (ara sezzjoni 5.1).
English: At a therapeutic dose of 300 mg once daily, the mean (CV) steady-state Cmax, Cmin and 24h AUC are 2.0 µg/ml (26%), 0.04 µg/ml (34%) and 8.9 µg•h/ml (21%), respectively.
Maltese: F'doża terapewtika ta' 300 mg li tingħata darba kuljum, listadju fiss medju (CV) ta' Cmax, Cmin u l-AUC fuq 24 siegħa huma 2.0 µg/mL (26%), 0.04 µg/mL
English: Musculoskeletal and connective tissue disorders Common: Arthralgia, muscle disorders.
Maltese: Komuni: Artralġja, disturbi fil-muskoli.
English: M184V mutants display greatly reduced susceptibility to lamivudine and show diminished viral replicative capacity in vitro.
Maltese: Mutanti tal-M184V juru suxxettibilta' mnaqqsa ħafna għal lamivudine u juru tnaqqis tal-ħila replikattiva virali in vitro.
English: The M184V RT mutant shows a <4-fold decrease in susceptibility to didanosine; the clinical significance of these findings is unknown.
Maltese: Il-mutant M184V RT juri tnaqqis ta' <4 darbiet fis-suxxettibilta' tiegħu għal didanosine; l-importanza klinika ta' dawn is-sejbiet mhix magħrufa.
English: These differences were observed in each different age group studied.
Maltese: Dawn iddifferenzi ġew osservati f'kull grupp differenti ta' età studjat.
English: In 60 healthy adult volunteers, lamivudine 300 mg once daily has been demonstrated to be pharmacokinetically equivalent at steady-state to lamivudine 150 mg twice daily with respect to intracellular triphosphate AUC24 and Cmax.
Maltese: F'60 volontier adult b'saħħithom, pillola ta' Lamivudine 300 mg li tingħata darba kuljum instabet li hi farmakinetikament ekwivalenti fi stadju fiss għal żewġ pilloli ta' lamivudine 150 mg li jingħataw kuljum fir-rigward ta' AUC24 u Cmax għal trifosfat intraċellulari.
English: Lamivudine is well absorbed from the gastrointestinal tract, and the bioavailability of oral lamivudine in adults is normally between 80 and 85%.
Maltese: Lamivudine hu assorbit sew mill-parti gastrointestinali, u l-bijodisponibilità ta' lamivudine li jittieħed mill-ħalq minn adulti hi normalment bejn 80 u 85%.
English: The adverse reactions considered at least possibly related to the treatment are listed below by body system, organ class and absolute frequency.
Maltese: Ir-reazzjonijiet avversi kkonsidrati li tal-anqas huma possibilment marbuta mat-trattament huma elenkati hawn isfel skont is-sistema tal-klassifika tal-organi u l-frekwenza assoluta.
English: The mean (CV) AUC over a dosing interval of 12 hours is 4.7 µg•h/ml (18%).
Maltese: L-AUC medju (CV) fuq intervall ta' dożaġġ għal 12-il siegħa hu 4.7 µg•h/mL (18%).
English: Clinical trial evidence from paediatric patients receiving lamivudine with other antiretroviral drugs (abacavir, nevirapine/efavirenz or zidovudine) has shown that the resistance profile observed in paediatric patients is similar to that observed in adults, in terms of the genotypic substitutions detected and their relative frequency.
Maltese: Evidenza ta' provi kliniċi minn pazjenti pedjatriċi li rċevew lamivudine ma' mediċini antiretrovirali oħrajn (abacavir, nevirapine/efavirenz jew zidovudine) uriet li l-profil tar-reżistenza osservat f'pazjenti pedjatriċi huwa simili għal dak osservat fl-adulti, f'termini tas-sostituzzjonijiet ġenetiċi mikxufin u l-frekwenza relattiva tagħhom.
English: Lamivudine 8 mg/kg OnceDaily Dosing Geometric Mean (95% Cl)
Maltese: Darba Kuljum ta' Lamivudine 8 mg/kg (95% Cl)
English: When possible, avoid chronic coadministration of Lamivudine Teva Pharma B.V. with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (e.g. xylitol, mannitol, lactitol,
Maltese: Meta possibbli, evita l-għoti flimkien kroniku ta' Lamivudine Teva Pharma B.V ma' prodotti mediċinali li fihom sorbitol jew polialkoħol ieħor b'azzjoni osmotika jew alkoħol monosakkaridu (eż. xylitol, mannitol, lactitol, maltitol).
English: Uncommon: Transient elevations in liver enzymes (AST, ALT).
Maltese: Mhux komuni: żieda mhux permanenti fil-livelli tal-enzimi tal-fwied (AST, ALT).
English: Lamivudine 4 mg/kg TwiceDaily Dosing Geometric Mean (95% Cl)
Maltese: Darbtejn Kuljum ta' Lamivudine 4 mg/kg (95% Cl)
English: The triphosphate has selective inhibitory activity against HIV-1 and HIV-2 replication in vitro, it is also active against zidovudine-resistant clinical isolates of HIV.
Maltese: It-trifosfat għandu attività inibitorja selettiva kontra r-replikazzjoni in vitro ta' l-HIV-1 u l-HIV-2; lamivudine hu wkoll attiv kontra iżolati kliniċi ta' l-HIV li huma reżistenti għal zidovudine.
English: Uncommon: Neutropenia and anaemia (both occasionally severe), thrombocytopenia.
Maltese: Mhux komuni: Newtropenja u anemija (kultant it-tnejn severi), tromboċitopenija.
English: In vitro lamivudine inhibits the intracellular phosphorylation of cladribine leading to a potential risk of cladribine loss of efficacy in case of combination in the clinical setting.
Maltese: In vitro lamivudine jinibixxi l-fosforilazzjoni intraċellulari ta' cladribine u dan iwassal għal riskju potenzjali ta' telf fl-effikaċja ta' cladribine fil-każ ta' kombinazzjoni fl-ambjent kliniku.
English: EU/1/09/596/001 EU/1/09/596/002 EU/1/09/596/003 EU/1/09/596/004 EU/1/09/596/005 EU/1/09/596/006 EU/1/09/596/007 EU/1/09/596/015
Maltese: EU/1/09/596/005 EU/1/09/596/006 EU/1/09/596/007 EU/1/09/596/015
English: A modest increase in Cmax (28%) was observed for zidovudine when administered with lamivudine, however overall exposure (AUC) is not significantly altered.
Maltese: Żieda modesta f'Cmax (28%) ġiet osservata għal zidovudine meta ngħata flimkien ma' lamivudine, madanakollu, l-espożizzjoni globali (AUC) ma ġietx mibdula b'mod sinifikanti.
English: Proportions of Subjects in the Once Daily versus Twice Daily Abacavir+Lamivudine Randomisation of ARROW with Plasma HIV-1 RNA <80 copies/ml: Subgroup Analysis by Formulation
Maltese: Randomizzazzjoni ta' ARROW bi Plasma HIV-1 RNA <80 kopja/ml: Analiżi tas-Sottogrupp permezz tal-Formulazzjoni
English: The likelihood of metabolic interactions of lamivudine with other medicinal products is low due to the small extent of hepatic metabolism (5-10%) and low plasma protein binding.
Maltese: Ftit hemm probabiltà ta' azzjoni metabolika reċiproka ta' lamivudine ma' prodotti mediċinali oħra minħabba l-okkorrenza baxxa (5-10%) ta' metaboliżmu tal-fwied u taqgħid baxx mal-proteina fil-plażma.
English: The likelihood of metabolic interactions is low due to limited metabolism and plasma protein binding and almost complete renal clearance.
Maltese: Il-probabilità ta' interazzjonijiet metaboliċi hi baxxa minħabba l-metaboliżmu u r-rabta tal-proteini mal-plażma limitati, u t-tneħħija kważi totali mill-kliewi.
English: Once Daily Plasma HIV-1 RNA <80 c/ml: n/N (%)
Maltese: Darba Kuljum RNA ta' HIV-1 filPlasma <80 kopja/ml: n/N (%)
English: Lamivudine Teva Pharma B.V. is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children.
Maltese: Lamivudine Teva Pharma B.V. huwa indikat bħala parti mit-terapija ta' kombinazzjoni antiretrovirali għat-trattament ta' adulti u tfal infettati bil-Vajrus tal-Immunodefiċjenza fil-Bniedem (HIV).
English: In vitro data tend to suggest that the continuation of lamivudine in anti-retroviral regimen despite the development of M184V might provide residual anti-retroviral activity (likely through impaired viral fitness).
Maltese: Tagħrif in vitro għandu t-tendenza li juri li l-kontinwazzjoni ta' lamivudine f'sistema ta' kura antiretrovirali minkejja li l-iżvilupp ta' M184V jista' jipprovdi attività antiretrovirali residwa (li tista' tiġri minħabba li l-virus ma jibqax jiffunzjona sewwa).
English: Teva Pharma, S.L.U Tél: +34 913873280
Maltese: Tél: +34 913873280
English: If Lamivudine Teva Pharma B.V. is discontinued in patients co-infected with hepatitis B virus, periodic monitoring of liver function tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in an acute exacerbation of hepatitis (see lamivudine 100 mg SmPC).
Maltese: Jekk Lamivudine Teva Pharma B.V. jitwaqqaf f'pazjenti ko-infettati bil-virus ta' epatite B, huwa rrakkomandat monitoraġġ perijodiku ta' testijiet għall-funzjoni tal-fwied u sustanzi li juru r-replikazzjoni ta' HBV, għaliex it-twaqqif ta' lamivudine jista' jikkawża li l-epatite tkompli tiħżien b'mod akut (ara l-SmPC ta' lamivudine 100 mg).
English: Creatinine clearance (ml/min) First dose
Maltese: (mL/min)
English: It belongs to a group of medicines called nucleoside analogue reverse transcriptase inhibitors (NRTIs).
Maltese: Huwa jagħmel parti minn grupp ta' mediċini msejħa nucleoside reverse transcriptase inhibitors (NRTIs).
English: • diarrhoea
Maltese: Pankreatite:
English: Lamivudine Teva Pharma B.V. is used to treat HIV (human immunodeficiency virus) infection in adults and children.
Maltese: Lamivudine Teva Pharma B.V. jintuża biex jikkura l-infezzjoni bl-HIV (virus talimmunodefiċjenza umana) fl-adulti u fit-tfal.
English: The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia).
Maltese: L-aktar reazzjonijiet avversi rrappurtati huma disturbi ematoloġiċi (anemija, newtropenja) u disturbi metaboliċi
English: Lamivudine has not been specifically investigated in HIV patients co-infected with HBV.
Maltese: Lamivudine ma ġiex mistħarreġ speċifikament f'pazjenti bl-HIV ko-infettati bl-HBV.
English: Co-administration of lamivudine with food results in a delay of tmax and a lower Cmax (decreased by 47%).
Maltese: It-teħid ta' lamivudine mal-ikel irriżulta f'dewmien ta' tmax u ta' Cmax aktar baxx (tnaqqas b' 47%).
English: These may affect up to 1 in 1000 people:
Maltese: Dawn jistgħu jaffettwaw sa persuna waħda minn kull 1,000:
English: Read the information ‘Other possible side effects of combination therapy for HIV' in section 4 of this leaflet.
Maltese: Aqra l-informazzjoni ‘Effetti sekondarji possibbli b'terapija b'taħlita ta' mediċini għall-HIV' f'sezzjoni 4 ta' dan il-fuljett.
English: Mitochondrial dysfunction following exposure in utero: Nucleoside and nucleotide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine.
Maltese: Analogi nukleosidi u nukleotidi jistgħu jaffettwaw il-funzjoni tal-mitokondrija sa grad varjabbli, li ġie innutat l-iktar bi stavudine, didanosine u zidovudine.
English: EU/1/09/596/008 EU/1/09/596/009 EU/1/09/596/010 EU/1/09/596/011 EU/1/09/596/012 EU/1/09/596/013 EU/1/09/596/014 EU/1/09/596/016
Maltese: EU/1/09/596/011 EU/1/09/596/012 EU/1/09/596/013 EU/1/09/596/014
English: The active ingredient in Lamivudine Teva Pharma B.V. is lamivudine.
Maltese: Is-sustanza attiva f'Lamivudine Teva Pharma B.V. hija lamivudine.
English: Lamivudine was not genotoxic in vivo at doses that gave plasma concentrations around 40-50 times higher than the anticipated clinical plasma levels.
Maltese: Lamivudine ma kienx ġenotossiku in vivo f'dożi li rriżultaw f'konċentrazzjonijiet fil-plażma ta' 40-50 darba iktar mil-livelli ta' plażma klinika antiċipati.
English: INFORMATION IN BRAILLE Lamivudine Teva Pharma B.V. 300 mg
Maltese: Lamivudine Teva Pharma B.V. 300 mg
English: The combination of lamivudine with cladribine is not-recommended (see section 4.5).
Maltese: Il-kombinazzjoni ta' lamivudine ma' cladribine mhijiex rakkomandata (ara sezzjoni 4.5). Eċċipjent(i)
English: Lamivudine metabolism does not involve CYP3A, making interactions with medicinal products metabolised by this system (e.g. PIs) unlikely.
Maltese: Il-metaboliżmu ta' lamivudine ma jinvolvix CYP3A, li jagħmilha improbabbli li jkun hemm effetti fuq prodotti mediċinali li jiġu metabolizzati b'din is-sistema (eż. PI).
English: Dosing recommendations - Adults, adolescents and children (weighing at least 25 kg):
Maltese: Rakkomandazzjonijiet dwar id-doża - Adulti, adolexxenti u tfal (li jiżnu tal-inqas 25 kg):
English: Children: The absolute bioavailability of lamivudine (approximately 58-66%) was reduced in paediatric patients below 12 years of age.
Maltese: Tfal: Il-bijodisponibbiltà assoluta ta' lamivudine (madwar 58-66%) kienet inqas f'pazjenti pedjatriċi li kellhom inqas minn 12-il sena.
English: The active moiety, intracellular lamivudine triphosphate, has a prolonged terminal half-life in the cell (16 to 19 hours) compared to the plasma lamivudine half-life (5 to 7 hours).
Maltese: Il-moijetà attiva, intraċellulari ta' lamivudine triphosphate, għandha half-life mtawwla fiċ-ċella (16 sa 19-il siegħa) meta mqabbal mal-ħalf-life ta' lamivudine fil-plażma (5 sa 7 sigħat).
English: MARKETING AUTHORISATION NUMBER(S) EU/1/09/596/007
Maltese: EU/1/09/596/007
English: Children (weighing less than 25 kg)
Maltese: Tfal (li jiżnu inqas minn 25 kg)
English: Lamivudine has been widely used as a component of antiretroviral combination therapy with other antiretroviral agents of the same class (NRTIs) or different classes (PIs, non-nucleoside reverse transcriptase inhibitors).
Maltese: Lamivudine ġie użat b'mod mill-aktar komuni bħala komponent f'terapija ta' kombinazzjoni antiretrovirali ma' sustanzi antiretrovirali oħra tal-istess kategorija (NRTIs) jew kategoriji oħra (PIs, inibituri ta'non-nucleoside reverse transcriptase).
English: Co-administration of lamivudine with high doses of co-trimoxazole for the treatment of Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis should be avoided.
Maltese: L-għoti ta' lamivudine flimkien ma' dożi qawwija ta co-trimoxazole għall-kura tal-pulmonite b'Pneumocystis jirovecii [PCP]) u toxoplażmożi għandu jiġi evitat.
English: Rare: Rhabdomyolysis.
Maltese: - Żomm dan il-fuljett.
English: Paediatric pharmacokinetic studies with both oral solution and tablet formulations have demonstrated that once daily dosing provides equivalent AUC0-24 to twice daily dosing of the same total daily dose.
Maltese: L-istudji dwar il farmakokinetika pedjatrika kemm bis-soluzzjoni orali kif ukoll bil-formolazzjonijiet tal-pilloli wrew li dożaġġ ta' darba kuljum jipprovdi AUC0-24 ekwivalenti għal darbtejn kuljum id-dożaġġ tal-istess doża totali ta' kuljum.
English: The nucleoside analogues (e.g. didanosine) like zidovudine, are not eliminated by this mechanism and are unlikely to interact with lamivudine.
Maltese: L-analogi nukleosidi (eż. didanosine) bħal zidovudine, ma jiġux eliminati b'dan il-mekkaniżmu u probabilment ma jiġux affettwati b'lamivudine.
English: Zidovudine has no effect on the pharmacokinetics of lamivudine (see section 5.2).
Maltese: Zidovudine m'għandux effett fuq il-farmakokinetiċi ta' lamivudine (ara sezzjoni 5.2).
English: INFORMATION IN BRAILLE Lamivudine Teva Pharma B.V. 150 mg
Maltese: Lamivudine Teva Pharma B.V 150 mg
English: Glomerular filtration estimates suggests that to achieve similar adult and paediatric exposure, an appropriate dose for children aged six weeks and older could be 8 mg/kg/day.
Maltese: L-istimi tal-filtrazzjoni glomerulari jissuġerixxu li sabiex ikun hemm espożizzjoni adulta u pedjatrika simili, id-doża xierqa għal tfal li għandhom sitt ġimgħat u aktar tista tkun ta' 8 mg/kg/jum.
English: Genotypic resistance analyses were conducted on samples with plasma HIV-1 RNA >1000 copies/ml.
Maltese: Saru analiżi dwar ir-reżistenza ġenotipika fuq kampjuni ta' RNA ta' HIV-1 fil-plażma ta' >1000 kopja/ml.
English: 20 film-coated tablets 30 film-coated tablets 60 film-coated tablets 80 film-coated tablets 90 film-coated tablets 100 film-coated tablets 500 film-coated tablets
Maltese: 20 pillola miksija b'rita 30 pillola miksija b'rita 60 pillola miksija b'rita 80 pillola miksija b'rita 90 pillola miksija b'rita 100 pillola miksija b'rita 500 pillola miksija b'rita
English: UAB Teva Baltics Tel: +370 52660203
Maltese: Tel: +370 52660203
English: Children receiving lamivudine oral solution concomitantly with other antiretroviral oral solutions in clinical trials developed viral resistance more frequently than children receiving tablets (see the description of the clinical experience in paediatric population (ARROW study) and section 5.2).
Maltese: Tfal li rċevew is-soluzzjoni orali ta' lamivudine b'mod konkomitanti ma' soluzzjonijiet orali antiretrovirali oħrajn fi provi kliniċi żviluppaw reżistenza virali aktar ta' spiss mit-tfal li rċevew il pilloli (ara d-deskrizzjoni tal-esperjenza klinika fil-popolazzjoni pedjatrika (studju ARROW) u sezzjoni 5.2).
English: Lamivudine Teva Pharma B.V. 300 mg film-coated tablets Grey, diamond shaped, biconvex film-coated tablet with approx. 18.0 mm length and 8.0 mm widthengraved with “L 300” on one side and plain on the other
Maltese: Pillola griża, f'għamla ta' djamant, imżaqqa fuq żewġ naħat u miksija b'rita, twila madwar 18.0 mm u wiesgħa madwar 8.0 mm, li fuqha hemm imnaqqax “L 300” fuq naħa waħda u mingħajr kitba fuq in-naħa l-oħra.
English: A recommended dosage regimen for patients with creatinine clearance below 50 ml/min is shown in the dosage section (see section 4.2).
Maltese: Hemm bżonn li titnaqqas id-doża f'pazjenti li ttneħħija tal-krejatinina tagħhom tkun ˂50 mL/min (ara sezzjoni 4.2).
English: This may be administered as either 150 mg twice daily or 300 mg once daily (see section 4.4).
Maltese: Dan jista' jingħata jew bħala 150 mg darbtejn kuljum jew inkella bħala 300 mg darba kuljum (ara sezzjoni 4.4).
English: Lamivudine exhibits linear pharmacokinetics over the therapeutic dose range and displays limited binding to the major plasma protein albumin (<16%-36% to serum albumin in in vitro studies).
Maltese: 32 L/h/kg , prinċipalment bi tneħħija mill-kliewi (>70%) permezz tas-sistema tat-trasport katijoniku organiku. Lamivudine juri farmakokinetiċi lineari fuq il-medda ta' dożi terapewtiċi u juri rabta limitata mal proteina ewlenija fil-plażma, l-albumina (<16%-36% għal albumina fis-serum fi studji in vitro).
English: Lamivudine Teva Pharma B.V. 300 mg film-coated tablets EU/1/09/596/008 20 tablets (blister) EU/1/09/596/009 30 tablets (blister) EU/1/09/596/010 60 tablets (blister) EU/1/09/596/011 90 tablets (blister) EU/1/09/596/012 100 tablets (blister) EU/1/09/596/013 500 tablets (blister) EU/1/09/596/014 30 tablets (bottle) EU/1/09/596/016 80 tablets(blister)
Maltese: Lamivudine Teva Pharma B.V. 300 mg pilloli miksija b'rita EU/1/09/596/008 20 pillola (folja) EU/1/09/596/009 30 pillola (folja)
English: Lamivudine Teva Pharma B.V. is available in aluminium blisters containing 20, 30, 60, 80, 90, 100 and 500 tablets or HDPE containers containing 60 tablets.
Maltese: BV jiġi f'folji tal-aluminju li fihom 20, 30, 60, 80, 90, 100 u 500 pillola jew kontenituri tal-pilloli tal-HDPE li fihom 60 pillola.
English: Lamivudine Teva Pharma B.V. is a type of medicine known as an antiretroviral.
Maltese: Lamivudine Teva Pharma B.V. huwa tip ta' mediċina magħrufa wkoll bħala antiretrovirali.
English: Rare: Angioedema.
Maltese: Rari ħafna: Aċidożi lattika.
English: • emtricitabine (used to treat HIV infection).
Maltese: • emtricitabine (jintuża biex jikkura infezzjoni bl-HIV).
English: Suomi/Finland Teva Finland Oy Puh/Tel: +358 201805900
Maltese: Pliva Ljubljana d.o.o. Tel: +386 15890390
English: Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterium infections, and Pneumocystis jirovecii pneumonia (often referred to as PCP).
Maltese: Eżempji rilevanti jinkludu retinite b'ċitomegalovirus, infezzjonijiet lokali jew mifruxa b'Mycobacterium, u pulmonite b'Pneumocystis jirovecii (ħafna drabi ssir referenza għaliha bħala PCP [Pneumocystis jirovecii pneumonia]).
English: INSTRUCTIONS ON USE
Maltese: Darba Kuljum u Darbtejn
English: Triple nucleoside therapy: There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when lamivudine was combined with tenofovir disoproxil fumarate and abacavir as well as with tenofovir disoproxil fumarate and didanosine as a once daily regimen.
Maltese: Kien hemm rapporti ta' rata ogħlja ta' falliment viroloġiku u ta' reżistenza murija fi stadju bikri meta lamivudine ngħata ma' tenofovir disoproxil fumarate u abacavir kif ukoll ma' tenofovir disoproxil fumarate u didanosine bħala programm ta' terapija ta' darba kuljum.
English: Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events.
Maltese: Pazjenti b'epatite kronika B jew Ċ li jkunu fuq terapija antiretrovirali kkombinata jkunu f'riskju akbar ta' avvenimenti avversi serji tal-fwied u li jistgħu ikunu fatali.
English: Lamivudine Teva Pharma B.V. is available in aluminium blisters containing 20, 30, 60, 80, 90, 100 and 500 tablets or HDPE containers containing 30 tablets.
Maltese: BV jiġi f'folji tal-aluminju li fihom 20, 30, 60, 80, 90, 100 u 500 pillola jew kontenituri tal-pilloli tal-HDPE li fihom 30 pillola.